Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter
Shares of Aldeyra Therapeutics plummeted nearly 75% Thursday morning after the Food and Drug Administration said the company's dry eye disease drug has not proven to be effective in enough studies.